Conexeu Sciences Opens New Vancouver R&D Hub to Boost Regenerative Tissue Platform
CNXU is trading near its 52-week low of $9.6 (14% above the low).
Summary
Conexeu Sciences has opened a new R&D facility in Vancouver, Canada, to accelerate development of its regenerative tissue platform, including the CXU™ platform and B.R.E.A.S.T.™ 3D-bioprinted breast matrix. This operational expansion follows the company's recent Nasdaq listing and a highly dilutive share offering to address a 'going concern' warning reported in its latest 10-Q. The new facility demonstrates continued investment in its preclinical-stage pipeline despite significant financial headwinds. The company anticipates a 510(k) submission for its initial indication in early 2027.
At the time of this announcement, CNXU was trading at $10.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $286M. The 52-week trading range was $9.60 to $18.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.